AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27207886 — intervention group
Group type: COMPARATOR
Intervention: Group A
Number of subjects: 80
Study 27207886 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 80
Study 23963633 — intervention group
Group type: EXPERIMENTAL
Intervention: 28.2 μg teriparatide
Number of subjects: 316
Study 23963633 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1.4 μg teriparatide)
Number of subjects: 316
Study 23358401 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I‐iodide activity calculated based on desired 'optimal' final thyroid mass (Group D)
Number of subjects: 147
Study 23358401 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 Gy absorbed thyroid dose (Group C)
Number of subjects: 147
Study 23358401 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 Gy absorbed thyroid dose (Group B)
Number of subjects: 147
Study 23358401 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 Gy absorbed thyroid dose (Group A)
Number of subjects: 147
Study 23358401 — intervention group
Group type: EXPERIMENTAL
Intervention: 131I‐iodide activity for Group C
Number of subjects: 147
Study 23358401 — intervention group
Group type: COMPARATOR
Intervention: 131I‐iodide activity for Group D
Number of subjects: 147
Study 20395842 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular Aneurysm Repair (EVAR)
Number of subjects: 1194
Study 20395842 — intervention group
Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 1194
Study 20395842 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 1194
Study 18234321 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) 200 microg twice daily
Number of subjects: 447
Study 16008596 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (TG) induction therapy (1.5 mg/kg/dose during the anhepatic period and QOD x2 doses)
Number of subjects: 22
Study 16008596 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (TG) induction therapy
Number of subjects: 22
Study 16008596 — intervention group
Group type: COMPARATOR
Intervention: No Thymoglobulin (control group)
Number of subjects: 22
Study 12974921 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump/beating heart surgery (Group II)
Number of subjects: 91
Study 12974921 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery (Group I)
Number of subjects: 91
Study 12974921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 10392509 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 78
Study 10392509 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 78
Study 8681616 — intervention group
Group type: EXPERIMENTAL
Intervention: External chest wall oscillation (ECWO) at 1 Hz
Number of subjects: 7
Study 8681616 — intervention group
Group type: COMPARATOR
Intervention: Cuirass without ECWO (Control)
Number of subjects: 7
Study 8375238 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation training
Number of subjects: 38
Study 8375238 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes treatment
Number of subjects: 38
Study 3079781 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide 25 mg four times/day
Number of subjects: 187
Study 3079781 — intervention group
Group type: COMPARATOR
Intervention: Quinidine 200 mg four times/day
Number of subjects: 187
Study 3079781 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide 50 mg four times/day (after dose adjustment)
Number of subjects: 187
Study 3079781 — intervention group
Group type: COMPARATOR
Intervention: Quinidine 400 mg four times/day (after dose adjustment)
Number of subjects: 187
Study 3079781 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 187
Study 3079781 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 187
Study 29806666 — intervention group
Group type: EXPERIMENTAL
Intervention: Central group (natural position)
Number of subjects: 30
Study 29806666 — intervention group
Group type: COMPARATOR
Intervention: Palatal group (3 mm more palatally)
Number of subjects: 30
Study 26304041 — intervention group
Group type: EXPERIMENTAL
Intervention: rLH 150 IU/day added to rFSH 300 IU/day and GnRH antagonist 0.25 mg/day
Number of subjects: 63
Study 26304041 — intervention group
Group type: COMPARATOR
Intervention: rFSH 300 IU/day and GnRH antagonist 0.25 mg/day (Control)
Number of subjects: 63
Study 23788002 — intervention group
Group type: EXPERIMENTAL
Intervention: ω-3 FA-enriched oral nutrition supplement (200 mL twice daily providing 2.0 g EPA and 1.0 g DHA per day)
Number of subjects: 0
Study 23788002 — intervention group
Group type: COMPARATOR
Intervention: Standard oral nutrition supplement (ONS)
Number of subjects: 0
Study 24531662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care 3 times weekly in addition to usual medical care
Number of subjects: 50
Study 24531662 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 50
Study 21767441 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg Lu AA21004
Number of subjects: 429
Study 21767441 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Lu AA21004
Number of subjects: 429
Study 21767441 — intervention group
Group type: EXPERIMENTAL
Intervention: 225 mg venlafaxine XR
Number of subjects: 429
Study 21767441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 19561345 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible three‐holed epidural catheter
Number of subjects: 500
Study 19561345 — intervention group
Group type: COMPARATOR
Intervention: Flexible end‐holed epidural catheter
Number of subjects: 500
Study 17467923 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial Brachytherapy (IB)
Number of subjects: 13
Study 17467923 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone Helical Tomotherapy (PT)
Number of subjects: 13
Study 17467923 — intervention group
Group type: COMPARATOR
Intervention: Three-Dimensional Conformal Radiotherapy (3D-CRT)
Number of subjects: 13
Study 17467923 — intervention group
Group type: COMPARATOR
Intervention: Supine Helical Tomotherapy (ST)
Number of subjects: 13
Study 17467923 — intervention group
Group type: EXPERIMENTAL
Intervention: All methods
Number of subjects: 13
Study 12478879 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-inositol, 12 g daily
Number of subjects: 11
Study 12478879 — intervention group
Group type: COMPARATOR
Intervention: Placebo (d‐glucose, 12 g daily)
Number of subjects: 11
Study 10531773 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms of purified Hepatitis B Surface Antigen (Euvax B, LG Chemicals) by i.m. injection in the deltoid (Group A)
Number of subjects: 61
Study 10531773 — intervention group
Group type: COMPARATOR
Intervention: 5 micrograms intra-dermally (Group B)
Number of subjects: 61
Study 8915800 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical steroids
Number of subjects: 75
Study 8915800 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal anti-inflammatory drugs (NSAIDs) and a soft contact lens
Number of subjects: 75
Study 8915800 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term NSAID administration
Number of subjects: 75
Study 8915800 — intervention group
Group type: EXPERIMENTAL
Intervention: Management suggestions for severe haze and regression and steroid-induced elevated intraocular pressure
Number of subjects: 75
Study 1810619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthguard 1
Number of subjects: 17
Study 1810619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthguard 2
Number of subjects: 17
Study 1810619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthguard 3
Number of subjects: 17
Study 1810619 — intervention group
Group type: COMPARATOR
Intervention: No mouthguard
Number of subjects: 17
Study 1810619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthguards (1, 2, 3) during heavy workload
Number of subjects: 17
Study 1810619 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouthguards (1, 2, 3) during light workload
Number of subjects: 17
Study 6136289 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam premedication
Number of subjects: 10
Study 6136289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31879855 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral scalp block with 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 89
Study 31879855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 30476030 — intervention group
Group type: EXPERIMENTAL
Intervention: Articles co-authored by statisticians
Number of subjects: 136
Study 30476030 — intervention group
Group type: COMPARATOR
Intervention: Articles not co-authored by statisticians
Number of subjects: 136
Study 29972002 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive therapy (acupuncture, acupoint injection, auricular point pressing)
Number of subjects: 126
Study 29972002 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 126
Study 29972002 — intervention group
Group type: COMPARATOR
Intervention: Western medication (oral mecobalamin, 0.5 mg, 3 times a day for 3 weeks)
Number of subjects: 126
Study 26518201 — intervention group
Group type: EXPERIMENTAL
Intervention: QoR‐15C
Number of subjects: 470
Study 26518201 — intervention group
Group type: COMPARATOR
Intervention: PQRS
Number of subjects: 470
Study 24485709 — intervention group
Group type: EXPERIMENTAL
Intervention: Active OIT (peanut flour; protein doses of 2-800 mg/day)
Number of subjects: 85
Study 24485709 — intervention group
Group type: COMPARATOR
Intervention: Control (peanut avoidance)
Number of subjects: 85
Study 24485709 — intervention group
Group type: EXPERIMENTAL
Intervention: Active OIT
Number of subjects: 85
Study 22077211 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion-SR
Number of subjects: 0
Study 22077211 — intervention group
Group type: COMPARATOR
Intervention: Buspirone
Number of subjects: 0
Study 19234106 — intervention group
Group type: EXPERIMENTAL
Intervention: Oropharyngeal exercises (n = 16)
Number of subjects: 31
Study 19234106 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (n = 15, control)
Number of subjects: 31
Study 17497371 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated strategies
Number of subjects: 85
Study 17497371 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsed strategies
Number of subjects: 85
Study 17497371 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics
Number of subjects: 85
Study 17497371 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic behavior
Number of subjects: 85
Study 17497371 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific strategies for optimal performance
Number of subjects: 85
Study 15250001 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified hollow stem (Group II)
Number of subjects: 42
Study 15250001 — intervention group
Group type: COMPARATOR
Intervention: Solid standard stem (Group I)
Number of subjects: 42
Study 12881939 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (avoided pacifiers)
Number of subjects: 281
Study 12881939 — intervention group
Group type: COMPARATOR
Intervention: Control group (used pacifiers)
Number of subjects: 281
Study 12881939 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily exposure to pacifiers
Number of subjects: 281
Study 9828799 — intervention group
Group type: EXPERIMENTAL
Intervention: Broadband ultrasound attenuation (BUA)
Number of subjects: 75
Study 9828799 — intervention group
Group type: EXPERIMENTAL
Intervention: Speed of sound (SOS)
Number of subjects: 75
Study 9828799 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD)
Number of subjects: 75
Study 7860469 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 15 mg/kg bodyweight/day for 30 days
Number of subjects: 30
Study 2064878 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 4.5 micrograms ml‐1
Number of subjects: 45
Study 2064878 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline 4.5 micrograms ml‐1
Number of subjects: 45
Study 2064878 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline plus fentanyl (4.5 micrograms ml‐1 of each)
Number of subjects: 45
Study 7055401 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of tinidazole (1600 mg) and doxycycline (400 mg) before operation
Number of subjects: 234
Study 7055401 — intervention group
Group type: COMPARATOR
Intervention: Five days of prophylaxis before operation
Number of subjects: 234
Study 31044556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralow dose CT (100 Sn kV and 96 mA)
Number of subjects: 88
Study 31044556 — intervention group
Group type: COMPARATOR
Intervention: Standard dose CT (110 kV and 50 mA)
Number of subjects: 88
Study 31522147 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional periodontal treatment (quadrant scaling and root planing - Q-SRP)
Number of subjects: 42
Study 31522147 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planing (FM-SRP)
Number of subjects: 42
Study 31522147 — intervention group
Group type: COMPARATOR
Intervention: Control group (periodontally healthy patients)
Number of subjects: 42
Study 27732056 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplement, taken twice daily for 8 weeks.
Number of subjects: 0
Study 24658475 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (10 weeks, 3 x 10 minutes per week)
Number of subjects: 66
Study 24658475 — intervention group
Group type: COMPARATOR
Intervention: Ergonomic training and education (usual care control group)
Number of subjects: 66
Study 22839109 — intervention group
Group type: EXPERIMENTAL
Intervention: Diesel combustion particles inhaled during spontaneous breathing
Number of subjects: 10
Study 19708629 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace and surgery treatment (BS group)
Number of subjects: 94
Study 19708629 — intervention group
Group type: COMPARATOR
Intervention: Surgery with no brace treatment (S group)
Number of subjects: 94
Study 17456685 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance combined with nerve stimulation (group US)
Number of subjects: 61
Study 17456685 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation alone (group ES)
Number of subjects: 61
Study 15045532 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone (AB)
Number of subjects: 72
Study 15045532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone substitution materials (BSM)
Number of subjects: 72
Study 15045532 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of AB and BSM
Number of subjects: 72
Study 15045532 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous SFEA and implantation
Number of subjects: 72
Study 15045532 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged approach after an average healing period of 6 months
Number of subjects: 72
Study 15045532 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative sinusitis
Number of subjects: 72
Study 15045532 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cumulative survival rate of SFEA
Number of subjects: 72
Study 11976463 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily iron therapy (335 mg of ferrous sulphate and 500 g folic acid)
Number of subjects: 40
Study 11976463 — intervention group
Group type: COMPARATOR
Intervention: Weekly iron therapy (335 mg of ferrous sulphate and 500 g folic acid)
Number of subjects: 40
Study 11976463 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily and weekly iron therapy
Number of subjects: 40
Study 9951030 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzol
Number of subjects: 1100
Study 9951030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study 8079014 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine treatment
Number of subjects: 60
Study 8079014 — intervention group
Group type: COMPARATOR
Intervention: Nicotine gum
Number of subjects: 60
Study 2729160 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% lactose formula
Number of subjects: 6
Study 2729160 — intervention group
Group type: COMPARATOR
Intervention: 50% lactose plus 50% glucose polymers formula
Number of subjects: 6
Study 31545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis based on patient-specific risk factors
Number of subjects: 0
Study 31545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation of anticoagulant therapy perioperatively
Number of subjects: 0
Study 31545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of epinephrine for digital anesthesia
Number of subjects: 0
Study 31545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean technique
Number of subjects: 0
Study 31545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical emollients and petroleum
Number of subjects: 0
Study 31545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternatives to elliptical excisions
Number of subjects: 0
Study 31545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound eversion
Number of subjects: 0
Study 31545388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of systemic retinoids
Number of subjects: 0
Study 28052773 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable activity monitor (Fitbit® Flex) combined with digital behaviour change resources
Number of subjects: 300
Study 28052773 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 300
Study 26304482 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise therapy (SET)
Number of subjects: 169
Study 23340042 — intervention group
Group type: EXPERIMENTAL
Intervention: NGT (nasogastric tube feeding)
Number of subjects: 35
Study 23340042 — intervention group
Group type: COMPARATOR
Intervention: NPO (nil per os)
Number of subjects: 35
Study 21314646 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain plasticity‐based computerized cognitive training program
Number of subjects: 487
Study 21314646 — intervention group
Group type: COMPARATOR
Intervention: Novelty‐ and intensity‐matched cognitive stimulation active control
Number of subjects: 487
Study 19624958 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 20
Study 19624958 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 20
Study 19624958 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelets
Number of subjects: 20
Study 19624958 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 20
Study 16875469 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurobloc (150 and 300 U)
Number of subjects: 10
Study 16875469 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox (3 and 4 U)
Number of subjects: 10
Study 16875469 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (12 U)
Number of subjects: 10
Study 16875469 — intervention group
Group type: COMPARATOR
Intervention: Pure saline
Number of subjects: 10
Study 13679688 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 30
Study 13679688 — intervention group
Group type: COMPARATOR
Intervention: Control (medical treatment)
Number of subjects: 30
Study 13679688 — intervention group
Group type: COMPARATOR
Intervention: Comparison between Immunotherapy and Control
Number of subjects: 30
Study 13679688 — intervention group
Group type: EXPERIMENTAL
Intervention: Total IgE and specific IgE levels
Number of subjects: 30
Study 11203593 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA gel
Number of subjects: 68
Study 11203593 — intervention group
Group type: EXPERIMENTAL
Intervention: Citric acid treatment
Number of subjects: 68
Study 11203593 — intervention group
Group type: COMPARATOR
Intervention: Control surgery only
Number of subjects: 68
Study 9323749 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment
Number of subjects: 174
Study 9323749 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 174
Study 9323749 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 174
Study 8385183 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ramipril with 12.5 mg HCT
Number of subjects: 581
Study 8385183 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg ramipril with 25 mg HCT
Number of subjects: 581
Study 8385183 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ramipril with 12.5 mg HCT
Number of subjects: 581
Study 8385183 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ramipril with 25 mg HCT
Number of subjects: 581
Study 8385183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with ramipril plus HCT
Number of subjects: 581
Study 8385183 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg HCT
Number of subjects: 581
Study 3544182 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-sclerosis variceal compression
Number of subjects: 40
Study 3544182 — intervention group
Group type: COMPARATOR
Intervention: No compression
Number of subjects: 40
Study 30477372 — intervention group
Group type: EXPERIMENTAL
Intervention: Swedish Colorectal Cancer Registry (SCRCR)
Number of subjects: 500
Study 27871236 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered after spinal anesthesia (Group A)
Number of subjects: 74
Study 27871236 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine administered before spinal anesthesia (Group B)
Number of subjects: 74
Study 24814039 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium chloride (30 mL of MgCl2 5% solution) once daily for 3 months
Number of subjects: 62
Study 24814039 — intervention group
Group type: COMPARATOR
Intervention: NaHCO3 0.1% solution (control) once daily for 3 months
Number of subjects: 62
Study 22739364 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (400 mg/day)
Number of subjects: 749
Study 22739364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 749
Study 20090540 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibreoptic bronchoscope (FOB)
Number of subjects: 41
Study 20090540 — intervention group
Group type: COMPARATOR
Intervention: Blind intubation device (BID)
Number of subjects: 41
Study 18216056 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS)
Number of subjects: 0
Study 18216056 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol component
Number of subjects: 0
Study 18216056 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone component
Number of subjects: 0